FGENのチャート
FGENの企業情報
| symbol | FGEN |
|---|---|
| 会社名 | FibroGen Inc （フィブロジェン） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 フィブロジェン（FibroGen Inc.）はファースト・イン・クラス治療薬のパイプラインを発見・開発する科学ベースのバイオ医薬品企業である。同社は貧血、線維性疾患、および癌の治療のための革新的医薬品を発展させるために、線維症および低酸素誘導因子（HIF）生物学および臨床開発に焦点を当てる。同社の最先端製品候補Roxadustatは慢性腎臓病（CKD）における貧血治療の第III相臨床開発におけるHIFプロリルヒドロキシラーゼ活性の経口小分子阻害剤で、低リスク骨髄異形成症候群の貧血 シンドローム（MDS）にある貧血の第III相発症に進む。同社はパムレブラブを開発した。パムレブラブは、臓器の機能不全および機能不全に至りうる持続性および過剰瘢痕を特徴とする慢性線維症および増殖性障害における共通因子である結合組織成長因子（CTGF）の活性を阻害する独自の治療用抗体である。 フィブロジェンは、研究に基づいた、米国のバイオ医薬品会社。深刻な医療領域を治療する新型治療薬の発見、開発、商業化に焦点を当てる研究を行う。様々な治療分野を対象に、複数のプログラムを生成する。製品候補は、経口低分子阻害剤｢roxadustat(FG-4592)｣がある。 fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. the company has built upon its extensive research experience in fibrosis and hypoxia-inducible factor (hif) biology to generate clinical programs targeting multiple therapeutic areas. fibrogen's most advanced product candidate, roxadustat (fg-4592), is an oral small molecule inhibitor of hif prolyl hydroxylases (hif-phs), in phase 3 clinical development for the treatment of anemia in chronic kidney disease (ckd). our second product candidate, fg-3019, is a monoclonal antibody in phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (ipf), pancreatic cancer and liver fibrosis. for more information please visit: www.fibrogen.com. |
| 本社所在地 | 409 Illinois Street San Francisco CA 94158 USA |
| 代表者氏名 | Thomas B. Neff トーマス・B・ネフ |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 415-978-1200 |
| 設立年月日 | 1993年 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2014年 |
| 従業員数 | 423人 |
| url | www.fibrogen.com |
| nasdaq_url | https://www.nasdaq.com/symbol/fgen |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -117.55900 |
| 終値（lastsale） | 52.4 |
| 時価総額（marketcap） | 4419070264.8 |
| 時価総額 | 時価総額（百万ドル） 4449.43 |
| 売上高 | 売上高（百万ドル） 145.65700 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 3891.987 |
| 当期純利益 | 当期純利益（百万ドル） -69.47500 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 FibroGen Inc revenues increased 27% to $75.9M. Net loss increased 4% to $64.8M. Revenues reflect License and milestone revenue increase from $0K to $14.3M Development and other revenue (includes increase of 3% to $61.6M. Higher net loss reflects Research and Development - increase of 14% to $94.8M (expense) Stock-based Compensation in R&D increase of 36% to $14.3M (expense). |
FGENのテクニカル分析
FGENのニュース
FibroGen raised to buy by Stifel ahead of Phase 3 data for pamrevlumab 2023/06/02 21:34:13 Seeking Alpha
FibroGen (FGEN) stock has been upgraded to buy by Stifel ahead of the expected release of data from two Phase 3 studies for its drug pamrevlumab. Read more here.
FibroGen''s Return on Invested Capital Overview 2023/05/23 14:46:58 Benzinga
Benzinga Pro data, FibroGen (NASDAQ: FGEN ) reported Q1 sales of $36.16 million. Earnings fell to a loss of $76.70 million, resulting in a 15.91% decrease from last quarter. In Q4, FibroGen brought in $34.37 million in sales but lost $66.17 million in earnings. What Is Return On Invested Capital? Return on Invested Capital is a measure of yearly pre-tax profit relative to capital invested by a business. Changes in earnings and sales indicate shifts in a company''s ROIC. A higher ROIC is generally representative of successful growth of a … Full story available on Benzinga.com
FibroGen Announces Positive Data From Phase 3 Study Of Roxadustat For Treatment Of Anemia 2023/05/18 12:42:00 Finanz Nachrichten
LONDON (dpa-AFX) - FibroGen Inc. (FGEN) announced positive data from its Phase 3 clinical study of roxadustat for treatment of anemia in patients receiving concurrent chemotherapy treatment for no…
FibroGen stock rises after roxadustat matches Sepo in Chinese trial for anemia 2023/05/18 12:20:30 Seeking Alpha
FibroGen''s (FGEN) oral drug roxadustat was good as recombinant erythropoietin alfa ((SEPO)) in improving hemoglobin level. Read more here
FibroGen, Inc. (FGEN) Q1 2023 Earnings Call Transcript 2023/05/09 03:14:06 Seeking Alpha
FibroGen, Inc. (NASDAQ:NASDAQ:FGEN) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ETCompany ParticipantsMichael Tung - Vice President, Corporate Strategy & Investor…
Fibrogen Inc (FGEN): Price Now Near $14.85; Daily Chart Shows An Uptrend on 50 Day Basis 2021/12/09 15:22:13 ETF Daily News
This move is a reversal from the hour prior, which saw price move up. The post Fibrogen Inc (FGEN): Price Now Near $14.85; Daily Chart Shows An Uptrend on 50 Day Basis appeared first on ETF Daily News .
Bank of America Corp DE Reduces Position in FibroGen, Inc. (NASDAQ:FGEN) 2021/12/06 09:24:41 Dakota Financial News
Bank of America Corp DE lessened its holdings in shares of FibroGen, Inc. (NASDAQ:FGEN) by 60.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 105,546 shares of the biopharmaceutical companys stock after selling 163,081 shares during the period. Bank []
FibroGen Inc. (NASDAQ: FGEN) Stock Price Forecast: $100 2021/11/27 18:00:00 Stocks Register
FibroGen Inc. (NASDAQ:FGEN) shares, rose in value on Friday, 11/26/21, with the stock price down by -5.66% to the previous days close as strong demand from buyers drove the stock to $12.17. Actively observing the price movement in the last trading, the stock closed the session at $12.90, falling within a range of $12.00 and FibroGen Inc. (NASDAQ: FGEN) Stock Price Forecast: $100 Read More »
UBS Asset Management Americas Inc. Has $2.19 Million Position in FibroGen, Inc. (NASDAQ:FGEN) 2021/11/19 11:20:46 Dakota Financial News
UBS Asset Management Americas Inc. reduced its position in shares of FibroGen, Inc. (NASDAQ:FGEN) by 13.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 82,249 shares of the biopharmaceutical companys stock after selling 12,539 shares during the period. UBS Asset []
Idiopathic Pulmonary Fibrosis Market 2021-2030: Exceptional Business Performance | Boehringer Ingelheim Pharma GmbH, and Co. Kg, MediciNova, FibroGen, Inc. 2021/09/09 08:58:35 OpenPR
Global Idiopathic Pulmonary Fibrosis Market Report published by Astute Analytica provides insight and updates about the corresponding segments involved in the global market for the forecast period of 2021-2030. A detailed analysis of the market dynamics is provided and comprehensive
Global Idiopathic Pulmonary Fibrosis (IPF) Market Analysis, Scope Significant Demand Foreseen by 2021-27 Market I Major key players-Biogen, Inc , Boehringer Ingelheim Gmbh , Bristol-Myers Squibb Company , Cipla Inc , F. Hoffmann-La Roche Ag , Fibrogen, In 2021/09/02 12:56:30 OpenPR
The study examines the global idiopathic pulmonary fibrosis market in detail, including current trends and forecasts, in order to identify potential investment opportunities. Idiopathic pulmonary fibrosis is an interstitial lung disease in which the lung tissues are destroyed, limiting the
The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration 2021/08/27 11:35:25 Benzinga
Here''s a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 26) Agenus Inc. (NASDAQ: AGEN ) Alkermes plc (NASDAQ: ALKS ) BeyondSpring Inc. (NASDAQ: BYSI ) ( moved on a co-development and commercialization agreement for chemotherapy-induced neutropenia treatment candidate) BioLife Solutions, Inc. (NASDAQ: BLFS ) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN ) DexCom, Inc. (NASDAQ: DXCM ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Erasca, Inc. (NASDAQ: ERAS ) Fulcrum Therapeutics, Inc. (NASDAQ: FULC ) Imago BioSciences, Inc. (NASDAQ: IMGO ) MiMedx Group, Inc. (NASDAQ: MDXG ) Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE ) Nuvalent, Inc. (NASDAQ: NUVL ) (IPOed July 29) PDS Biotechnology Corporation (NASDAQ: PDSB ) Prothena Corporation plc (NASDAQ: PRTA ) Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) Repligen Corporation (NASDAQ: RGEN ) ShockWave Medical, Inc. (NASDAQ: SWAV ) Zentalis Pharmaceuticals, Inc. (NASDAQ: ZNTL ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 26) Alzamend Neuro, Inc. (NASDAQ: ALZN ) Edgewise Therapeutics, Inc. (NASDAQ: EWTX ) FibroGen, Inc. (NASDAQ: FGEN ) MaxCyte, Inc. (NASDAQ: MXCT ) Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM ) Theravance Biopharma, Inc. (NASDAQ: TBPH ) TScan Therapeutics, Inc. (NASDAQ: TCRX ) Stocks In Focus Immutep Announces Award of Chinese Patent For Out-licensed Antibody Treatment Candidate For Cancer and Infectious Disease Immutep Limited (NASDAQ: IMMP ) announced the grant of a patent entitled "Antibody molecules to LAG-3 and uses thereof"
After FDA Rejection, EMA Approves FibroGen-Astellas'' Roxadustat 2021/08/20 13:19:43 Benzinga
The European Commission (EC) has approved FibroGen Inc (NASDAQ: FGEN ) and Astellas Pharma''s (OTC: ALPMF ) Evrenzo (roxadustat) for anemia caused by chronic kidney disease (CKD), just days after the FDA turned down the drug. Related: FDA Shoots Down Full story available on Benzinga.com